Benjamin W Van Tassell

List of Publications by Year in Descending Order

139 papers	5,898 citations	45 h-index	73 g-index
167 ext. papers	7,682 ext. citations	5.4 avg, IF	5.89 L-index

#	Paper	IF	Citations
139	Influence of extracellular volume fraction on peak exercise oxygen pulse following thoracic radiotherapy.. *Cardio-Oncology*, **2022**, 8, 1	2.8	0
138	Effect of interleukin-1 blockade with anakinra on leukocyte count in patients with ST-segment elevation acute myocardial infarction.. *Scientific Reports*, **2022**, 12, 1254	4.9	2
137	Heart failure clinical trial enrollment at a rural satellite hospital.. *Contemporary Clinical Trials*, **2022**, 115, 106731	2.3	
136	Interleukin-1 blockade in cardiac sarcoidosis: study design of the multimodality assessment of granulomas in cardiac sarcoidosis: Anakinra Randomized Trial (MAGiC-ART). *Journal of Translational Medicine*, **2021**, 19, 460	8.5	0
135	Targeting the NLRP3 inflammasome in cardiovascular diseases.. *Pharmacology & Therapeutics*, **2021**, 236, 108053	13.9	6
134	Meta-analysis of clinical outcomes of PCSK9 modulators in patients with established ASCVD. *Pharmacotherapy*, **2021**,	5.8	5
133	Interleukin-1 blockade with Anakinra and heart failure following ST-segment elevation myocardial infarction: results from a pooled analysis of the VCUART clinical trials. *European Heart Journal - Cardiovascular Pharmacotherapy*, **2021**,	6.4	5
132	Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19: JACC State-of-the-Art Review. *Journal of the American College of Cardiology*, **2021**, 78, 1635-1654	15.1	9
131	Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review. *Journal of the American College of Cardiology*, **2021**, 77, 1903-1921	15.1	84
130	Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial. *JAMA - Journal of the American Medical Association*, **2021**, 325, 1620-1630	27.4	235
129	Intermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial. *Thrombosis and Haemostasis*, **2021**,	7	21
128	Edema Index Predicts Cardiorespiratory Fitness in Patients With Heart Failure With Reduced Ejection Fraction and Type 2 Diabetes Mellitus. *Journal of the American Heart Association*, **2021**, 10, e018631	6	3
127	Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. *Nature Reviews Immunology*, **2021**, 21, 319-329	36.5	192
126	A phase 1 clinical trial of SP16, a first-in-class anti-inflammatory LRP1 agonist, in healthy volunteers. *PLoS ONE*, **2021**, 16, e0247357	3.7	3
125	Time of Eating and Cardiorespiratory Fitness in Patients with Heart Failure With Preserved Ejection Fraction and Obesity. *Current Developments in Nutrition*, **2021**, 5, 465-465	0.4	78
124	Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial. *Lancet Rheumatology, The*, **2021**, 3, e410-e418	14.2	29
123	Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19: A Randomized Clinical Trial. *JAMA - Journal of the American Medical Association*, **2021**, 326, 230-239	27.4	51

122	Time of eating and cardiorespiratory fitness in patients with heart failure with preserved ejection fraction and obesity. *Nutrition, Metabolism and Cardiovascular Diseases*, **2021**, 31, 2471-2473	4.5	0
121	Cardiovascular Complications of COVID-19: Pharmacotherapy Perspective. *Cardiovascular Drugs and Therapy*, **2021**, 35, 249-259	3.9	16
120	The Chronic Kidney Disease Phenotype of HFpEF: Unique Cardiac Characteristics. *American Journal of Cardiology*, **2021**, 142, 143-145	3	1
119	Diastolic Dysfunction Contributes to Impaired Cardiorespiratory Fitness in Patients with Lung Cancer and Reduced Lung Function Following Chest Radiation. *Lung*, **2021**, 199, 403-407	2.9	1
118	Safety and Preliminary Efficacy of Lorcaserin for Cocaine Use Disorder: A Phase I Randomized Clinical Trial. *Frontiers in Psychiatry*, **2021**, 12, 666945	5	3
117	Preservation of Cardiac Reserve and Cardiorespiratory Fitness in Patients With Acute De Novo Versus Acute on Chronic Heart Failure With Reduced Ejection Fraction. *American Journal of Cardiology*, **2021**, 158, 74-80	3	0
116	Effect of Canagliflozin Compared With Sitagliptin on Serum Lipids in Patients with Type 2 Diabetes Mellitus and Heart Failure with Reduced Ejection Fraction: A Post-Hoc Analysis of the CANA-HF Study. *Journal of Cardiovascular Pharmacology*, **2021**, 78, 407-410	3.1	
115	Use of novel antithrombotic agents for COVID-19: Systematic summary of ongoing randomized controlled trials. *Journal of Thrombosis and Haemostasis*, **2021**, 19, 3080-3089	15.4	3
114	Pericarditis Recurrence After Initial Uncomplicated Clinical Course. *American Journal of Cardiology*, **2021**, 160, 112-116	3	1
113	Effect of a Physician/Pharmacist Collaborative Care Model on Time in Target Range for Systolic Blood Pressure: Post Hoc Analysis of the CAPTION Trial. *Hypertension*, **2021**, 78, 966-972	8.5	2
112	Clinical trial enrollment at a rural satellite hospital during COVID-19 pandemic. *Journal of Clinical and Translational Science*, **2021**, 5, e136	0.4	3
111	The effects of canagliflozin compared to sitagliptin on cardiorespiratory fitness in type 2 diabetes mellitus and heart failure with reduced ejection fraction: The CANA-HF study. *Diabetes/Metabolism Research and Reviews*, **2020**, 36, e3335	7.5	10
110	Increased C-reactive protein is associated with the severity of thoracic radiotherapy-induced cardiomyopathy. *Cardio-Oncology*, **2020**, 6, 2	2.8	7
109	Interleukin-1 Blockade Inhibits the Acute Inflammatory Response in Patients With ST-Segment-Elevation Myocardial Infarction. *Journal of the American Heart Association*, **2020**, 9, e014941	6	64
108	Efficacy of different doses of omega-3 fatty acids on cardiovascular outcomes: rationale and design of a network meta-analysis. *Minerva Cardioangiologica*, **2020**, 68, 47-50	1.1	2
107	Cardiovascular Considerations in Treating Patients With Coronavirus Disease 2019 (COVID-19). *Journal of Cardiovascular Pharmacology*, **2020**, 75, 359-367	3.1	33
106	Phase 1B, Randomized, Double-Blinded, Dose Escalation, Single-Center, Repeat Dose Safety and Pharmacodynamics Study of the Oral NLRP3 Inhibitor Dapansutrile in Subjects With NYHA II-III Systolic Heart Failure. *Journal of Cardiovascular Pharmacology*, **2020**, 77, 49-60	3.1	25
105	Determinants of Cardiorespiratory Fitness in Patients with Heart Failure Across a Wide Range of Ejection Fractions. *American Journal of Cardiology*, **2020**, 125, 76-81	3	5

104	Determinants of Cardiorespiratory Fitness Following Thoracic Radiotherapy in Lung or Breast Cancer Survivors. *American Journal of Cardiology*, **2020**, 125, 988-996	3	12
103	Impact of a pharmacist-physician collaborative care model on time-in-therapeutic blood pressure range in patients with hypertension. *JACCP Journal of the American College of Clinical Pharmacy*, **2020**, 3, 404-409	1.4	4
102	Could recruiting former college athletes be the answer to less pharmacy student burnout?. *Currents in Pharmacy Teaching and Learning*, **2020**, 12, 357-362	1.5	0
101	Targeting GM-CSF in COVID-19 Pneumonia: Rationale and Strategies. *Frontiers in Immunology*, **2020**, 11, 1625	8.4	64
100	Acute Effects of Interleukin-1 Blockade Using Anakinra in Patients With Acute Pericarditis. *Journal of Cardiovascular Pharmacology*, **2020**, 76, 50-52	3.1	11
99	Clinical Presentation and Outcomes of Acute Pericarditis in a Large Urban Hospital in the United States of America. *Chest*, **2020**, 158, 2556-2567	5.3	17
98	Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease. *Circulation Research*, **2020**, 126, 1260-1280	15.7	165
97	Unsaturated Fatty Acids to Improve Cardiorespiratory Fitness in Patients With Obesity and HFpEF: The UFA-Preserved Pilot Study. *JACC Basic To Translational Science*, **2019**, 4, 563-565	8.7	16
96	Potential role for interleukin-1 in the cardio-renal syndrome. *European Journal of Heart Failure*, **2019**, 21, 385-386	12.3	5
95	Metabolic modulation predicts heart failure tests performance. *PLoS ONE*, **2019**, 14, e0218153	3.7	13
94	Omega-3 Red Blood Cell Content Is Associated with Fat Mass Index and Leptin in Subjects with Obesity and Heart Failure with Preserved Ejection Fraction (P21-001-19). *Current Developments in Nutrition*, **2019**, 3,	0.4	78
93	Pharmacokinetics of L-Triiodothyronine in Patients Undergoing Thyroid Hormone Therapy Withdrawal. *Thyroid*, **2019**, 29, 1371-1379	6.2	11
92	Educational Outcomes Resulting From Restructuring a Scholarship Course for Doctor of Pharmacy Students. *American Journal of Pharmaceutical Education*, **2019**, 83, 7246	2.5	3
91	Alirocumab in Acute Myocardial Infarction: Results From the Virginia Commonwealth University Alirocumab Response Trial (VCU-AlirocRT). *Journal of Cardiovascular Pharmacology*, **2019**, 74, 266-269	3.1	11
90	Noninvasive Hemodynamic Monitoring of Cocaine-Induced Changes in Cardiac Output and Systemic Vascular Resistance in Subjects With Chronic Cocaine Use Disorder. *Journal of Cardiovascular Pharmacology*, **2019**, 74, 528-534	3.1	1
89	The NLRP3 Inflammasome Inhibitor, OLT1177 (Dapansutrile), Reduces Infarct Size and Preserves Contractile Function After Ischemia Reperfusion Injury in the Mouse. *Journal of Cardiovascular Pharmacology*, **2019**, 73, 215-222	3.1	51
88	Dietary Bioactive Fatty Acids as Modulators of Immune Function: Implications on Human Health. *Nutrients*, **2019**, 11,	6.7	33
87	IL-1 Blockade Reduces Inflammation in Pulmonary Arterial Hypertension and Right Ventricular Failure: A Single-Arm, Open-Label, Phase IB/II Pilot Study. *American Journal of Respiratory and Critical Care Medicine*, **2019**, 199, 381-384	10.2	51

86	Relation of Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease to Left Ventricular Diastolic Function and Exercise Tolerance. *American Journal of Cardiology*, **2019**, 123, 466-473	3	17
85	Effects of empagliflozin on cardiorespiratory fitness and significant interaction of loop diuretics. *Diabetes, Obesity and Metabolism*, **2018**, 20, 2014-2018	6.7	13
84	Low NT-proBNP levels in overweight and obese patients do not rule out a diagnosis of heart failure with preserved ejection fraction. *ESC Heart Failure*, **2018**, 5, 372-378	3.7	33
83	Effect of intensive blood pressure control in patients with type 2 diabetes mellitus over 9 years of follow-up: A subgroup analysis of high-risk ACCORDION trial participants. *Diabetes, Obesity and Metabolism*, **2018**, 20, 1499-1502	6.7	21
82	Pharmacist-physician collaborative care model and time to goal blood pressure in the uninsured population. *Journal of Clinical Hypertension*, **2018**, 20, 88-95	2.3	14
81	Interleukin-1 blockade for the treatment of pericarditis. *European Heart Journal - Cardiovascular Pharmacotherapy*, **2018**, 4, 46-53	6.4	32
80	Levosimendan in Advanced Heart Failure: Where Do We Stand?. *Journal of Cardiovascular Pharmacology*, **2018**, 71, 127-128	3.1	2
79	Usefulness of Canakinumab to Improve Exercise Capacity in Patients With Long-Term Systolic Heart Failure and Elevated C-Reactive Protein. *American Journal of Cardiology*, **2018**, 122, 1366-1370	3	35
78	Effect of Interleukin-1 Blockade on Left Ventricular Systolic Performance and Work: A Post Hoc Pooled Analysis of 2 Clinical Trials. *Journal of Cardiovascular Pharmacology*, **2018**, 72, 68-70	3.1	11
77	Rationale and design of the Virginia Commonwealth University-Anakinra Remodeling Trial-3 (VCU-ART3): A randomized, placebo-controlled, double-blinded, multicenter study. *Clinical Cardiology*, **2018**, 41, 1004-1008	3.3	32
76	An Orally Available NLRP3 Inflammasome Inhibitor Prevents Western Diet-Induced Cardiac Dysfunction in Mice. *Journal of Cardiovascular Pharmacology*, **2018**, 72, 303-307	3.1	14
75	C-Reactive Protein and N-Terminal Pro-brain Natriuretic Peptide Levels Correlate With Impaired Cardiorespiratory Fitness in Patients With Heart Failure Across a Wide Range of Ejection Fraction. *Frontiers in Cardiovascular Medicine*, **2018**, 5, 178	5.4	10
74	IL-1 Blockade in Patients With Heart Failure With Preserved Ejection Fraction. *Circulation: Heart Failure*, **2018**, 11, e005036	7.6	76
73	The 2017 American College of Cardiology/American Heart Association hypertension guideline and opportunities for community pharmacists. *Journal of the American Pharmacists Association: JAPhA*, **2018**, 58, 382-386	1.7	7
72	Response to Comment on Buckley et al. Intensive Versus Standard Blood Pressure Control in SPRINT-Eligible Participants of ACCORD-BP. Diabetes Care 2017;40:1733-1738. *Diabetes Care*, **2018** , 41, e86-e87	14.6	2
71	Unsupervised analysis of combined lipid and coagulation data reveals coagulopathy subtypes among dialysis patients. *Journal of Lipid Research*, **2017**, 58, 586-599	6.3	10
70	Dietary Fat, Sugar Consumption, and Cardiorespiratory Fitness in Patients With Heart Failure With Preserved Ejection Fraction. *JACC Basic To Translational Science*, **2017**, 2, 513-525	8.7	31
69	Intensive Versus Standard Blood Pressure Control in SPRINT-Eligible Participants of ACCORD-BP. *Diabetes Care*, **2017**, 40, 1733-1738	14.6	73

68	Impaired myocardial relaxation with exercise determines peak aerobic exercise capacity in heart failure with preserved ejection fraction. *ESC Heart Failure*, **2017**, 4, 351-355	3.7	13
67	Interleukin-1 Blockade in Recently Decompensated Systolic Heart Failure: Results From REDHART (Recently Decompensated Heart Failure Anakinra Response Trial). *Circulation: Heart Failure*, **2017**, 10,	7.6	114
66	Lack of soluble circulating cardiodepressant factors in takotsubo cardiomyopathy. *Autonomic Neuroscience: Basic and Clinical*, **2017**, 208, 170-172	2.4	10
65	Low-Density Lipoprotein Receptor-Related Protein-1 Is a Therapeutic Target in Acute Myocardial Infarction. *JACC Basic To Translational Science*, **2017**, 2, 561-574	8.7	20
64	Interleukin-1 blockade in heart failure with preserved ejection fraction: rationale and design of the Diastolic Heart Failure Anakinra Response Trial 2 (D-HART2). *Clinical Cardiology*, **2017**, 40, 626-632	3.3	42
63	Obesity Contributes to Exercise Intolerance in Heart Failure With Preserved Ejection Fraction. *Journal of the American College of Cardiology*, **2016**, 68, 2487-2488	15.1	37
62	Effectiveness of a Pharmacist-Physician Team-Based Collaboration to Improve Long-Term Blood Pressure Control at an Inner-City Safety-Net Clinic. *Pharmacotherapy*, **2016**, 36, 342-7	5.8	18
61	Inflammatory markers in ST-elevation acute myocardial infarction. *European Heart Journal: Acute Cardiovascular Care*, **2016**, 5, 382-95	4.3	33
60	Inhibition of the NLRP3 inflammasome limits the inflammatory injury following myocardial ischemia-reperfusion in the mouse. *International Journal of Cardiology*, **2016**, 209, 215-20	3.2	137
59	Interleukin-1 Blockade in Acute Decompensated Heart Failure: A Randomized, Double-Blinded, Placebo-Controlled Pilot Study. *Journal of Cardiovascular Pharmacology*, **2016**, 67, 544-51	3.1	73
58	Recombinant Human Alpha-1 Antitrypsin-Fc Fusion Protein Reduces Mouse Myocardial Inflammatory Injury After Ischemia-Reperfusion Independent of Elastase Inhibition. *Journal of Cardiovascular Pharmacology*, **2016**, 68, 27-32	3.1	16
57	A review of PCSK9 inhibition and its effects beyond LDL receptors. *Journal of Clinical Lipidology*, **2016**, 10, 1073-80	4.9	30
56	A high-sugar and high-fat diet impairs cardiac systolic and diastolic function in mice. *International Journal of Cardiology*, **2015**, 198, 66-9	3.2	50
55	A mouse model of heart failure with preserved ejection fraction due to chronic infusion of a low subpressor dose of angiotensin II. *American Journal of Physiology - Heart and Circulatory Physiology*, **2015**, 309, H771-8	5.2	28
54	Targeting interleukin-1 in heart failure and inflammatory heart disease. *Current Heart Failure Reports*, **2015**, 12, 33-41	2.8	56
53	Iloprost reverses established fibrosis in experimental right ventricular failure. *European Respiratory Journal*, **2015**, 45, 449-62	13.6	54
52	Pharmacologic and surgical interventions to improve functional capacity in heart failure. *Heart Failure Clinics*, **2015**, 11, 117-24	3.3	8
51	Pharmacologic Inhibition of the NLRP3 Inflammasome Preserves Cardiac Function After Ischemic and Nonischemic Injury in the Mouse. *Journal of Cardiovascular Pharmacology*, **2015**, 66, 1-8	3.1	100

50	Role of Interleukin-1 in Radiation-Induced Cardiomyopathy. *Molecular Medicine*, **2015**, 21, 210-8	6.2	18
49	Independent roles of the priming and the triggering of the NLRP3 inflammasome in the heart. *Cardiovascular Research*, **2015**, 105, 203-12	9.9	50
48	Heart failure with preserved ejection fraction: refocusing on diastole. *International Journal of Cardiology*, **2015**, 179, 430-40	3.2	73
47	Predicting therapeutic response in patients with heart failure: the story of C-reactive protein. *Expert Review of Cardiovascular Therapy*, **2015**, 13, 153-61	2.5	9
46	Anti-inflammatory strategies for ventricular remodeling following ST-segment elevation acute myocardial infarction. *Journal of the American College of Cardiology*, **2014**, 63, 1593-603	15.1	177
45	Colchicine in stable chronic heart failure. *JACC: Heart Failure*, **2014**, 2, 538	7.9	
44	Interleukin-18 mediates interleukin-1-induced cardiac dysfunction. *American Journal of Physiology - Heart and Circulatory Physiology*, **2014**, 306, H1025-31	5.2	88
43	Treatment of group I pulmonary arterial hypertension with carvedilol is safe. *American Journal of Respiratory and Critical Care Medicine*, **2014**, 189, 1562-4	10.2	52
42	Interleukin-10 in patients with ST-segment elevation myocardial infarction. *International Journal of Cardiology*, **2014**, 172, e6-8	3.2	5
41	Induction of microRNA-21 with exogenous hydrogen sulfide attenuates myocardial ischemic and inflammatory injury in mice. *Circulation: Cardiovascular Genetics*, **2014**, 7, 311-20		84
40	Interleukin-18 as a therapeutic target in acute myocardial infarction and heart failure. *Molecular Medicine*, **2014**, 20, 221-9	6.2	86
39	Leukocyte activity in patients with ST-segment elevation acute myocardial infarction treated with anakinra. *Molecular Medicine*, **2014**, 20, 486-9	6.2	9
38	Response to letter regarding article, "targeting interleukin-1 in heart disease". *Circulation*, **2014**, 130, e63	16.7	2
37	A novel pharmacologic inhibitor of the NLRP3 inflammasome limits myocardial injury after ischemia-reperfusion in the mouse. *Journal of Cardiovascular Pharmacology*, **2014**, 63, 316-322	3.1	180
36	Interleukin-1β blockade improves left ventricular systolic/diastolic function and restores contractility reserve in severe ischemic cardiomyopathy in the mouse. *Journal of Cardiovascular Pharmacology*, **2014**, 64, 1-6	3.1	57
35	Clinical predictors of response to anakinra in patients with heart failure. *International Journal of Cardiology*, **2014**, 173, 537-9	3.2	6
34	Formation of the inflammasome in acute myocarditis. *International Journal of Cardiology*, **2014**, 171, e119-21	3.2	49
33	Interleukin-1 blockade in rheumatoid arthritis and heart failure: a missed opportunity?. *International Journal of Cardiology*, **2014**, 171, e125-6	3.2	16

32	Interleukin-1β induces a reversible cardiomyopathy in the mouse. *Inflammation Research*, **2013**, 62, 637-40	7.2	75
31	Galectin-1 controls cardiac inflammation and ventricular remodeling during acute myocardial infarction. *American Journal of Pathology*, **2013**, 182, 29-40	5.8	64
30	Metabolic gene remodeling and mitochondrial dysfunction in failing right ventricular hypertrophy secondary to pulmonary arterial hypertension. *Circulation: Heart Failure*, **2013**, 6, 136-44	7.6	134
29	Targeting interleukin-1 in heart disease. *Circulation*, **2013**, 128, 1910-23	16.7	202
28	Interleukin-1β blockade improves cardiac remodelling after myocardial infarction without interrupting the inflammasome in the mouse. *Experimental Physiology*, **2013**, 98, 734-45	2.4	73
27	Intracellular function of interleukin-1 receptor antagonist in ischemic cardiomyocytes. *PLoS ONE*, **2013**, 8, e53265	3.7	12
26	Comparative cardiac toxicity of anthracyclines in vitro and in vivo in the mouse. *PLoS ONE*, **2013**, 8, e58421	3.7	35
25	GS-6201, a selective blocker of the A2B adenosine receptor, attenuates cardiac remodeling after acute myocardial infarction in the mouse. *Journal of Pharmacology and Experimental Therapeutics*, **2012**, 343, 587-95	4.7	47
24	Right ventricular systolic dysfunction in patients with reperfused ST-segment elevation acute myocardial infarction. *International Journal of Cardiology*, **2012**, 155, 314-6	3.2	6
23	A mouse model of radiation-induced cardiomyopathy. *International Journal of Cardiology*, **2012**, 156, 231-3	3.2	27
22	Blocking interleukin-1 as a novel therapeutic strategy for secondary prevention of cardiovascular events. *BioDrugs*, **2012**, 26, 217-33	7.9	53
21	Recombinant human interleukin-1 receptor antagonist provides cardioprotection during myocardial ischemia reperfusion in the mouse. *Cardiovascular Drugs and Therapy*, **2012**, 26, 273-6	3.9	29
20	Inhibition of apoptosis signal-regulating kinase 1 reduces myocardial ischemia-reperfusion injury in the mouse. *Journal of the American Heart Association*, **2012**, 1, e002360	6	35
19	Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure. *PLoS ONE*, **2012**, 7, e33438	3.7	145
18	Blocking Interleukin-1 as a Novel Therapeutic Strategy for Secondary Prevention of Cardiovascular Events **2012**, 26, 217		2
17	Alpha-1 antitrypsin inhibits caspase-1 and protects from acute myocardial ischemia-reperfusion injury. *Journal of Molecular and Cellular Cardiology*, **2011**, 51, 244-51	5.8	108
16	Altered oxido-reductive state in the diabetic heart: loss of cardioprotection due to protein disulfide isomerase. *Molecular Medicine*, **2011**, 17, 1012-21	6.2	23
15	Alterations in the interleukin-1/interleukin-1 receptor antagonist balance modulate cardiac remodeling following myocardial infarction in the mouse. *PLoS ONE*, **2011**, 6, e27923	3.7	53

14	The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 19725-30	11.5	403
13	Silencing of hypoxia-inducible factor-1 gene attenuated angiotensin II-induced renal injury in Sprague-Dawley rats. *Hypertension*, **2011**, 58, 657-64	8.5	61
12	Right ventricular dysfunction following acute myocardial infarction in the absence of pulmonary hypertension in the mouse. *PLoS ONE*, **2011**, 6, e18102	3.7	30
11	Interleukin-1beta modulation using a genetically engineered antibody prevents adverse cardiac remodelling following acute myocardial infarction in the mouse. *European Journal of Heart Failure*, **2010**, 12, 319-22	12.3	86
10	Limited value of brain natriuretic peptide as a prognostic marker in acute heart failure--a meta-analysis. *International Journal of Cardiology*, **2010**, 145, 540-1	3.2	2
9	Pharmacologic inhibition of phosphoinositide 3-kinase gamma (PI3K) promotes infarct resorption and prevents adverse cardiac remodeling after myocardial infarction in mice. *Journal of Cardiovascular Pharmacology*, **2010**, 56, 651-8	3.1	22
8	Interleukin-1 trap attenuates cardiac remodeling after experimental acute myocardial infarction in mice. *Journal of Cardiovascular Pharmacology*, **2010**, 55, 117-22	3.1	62
7	Pharmacologic inhibition of myeloid differentiation factor 88 (MyD88) prevents left ventricular dilation and hypertrophy after experimental acute myocardial infarction in the mouse. *Journal of Cardiovascular Pharmacology*, **2010**, 55, 385-90	3.1	45
6	Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study). *American Journal of Cardiology*, **2010**, 105, 1371-1377.e1	3	279
5	Nutrition and heart failure: impact of drug therapies and management strategies. *Nutrition in Clinical Practice*, **2009**, 24, 60-75	3.6	30
4	Parecoxib inhibits apoptosis in acute myocardial infarction due to permanent coronary ligation but not due to ischemia-reperfusion. *Journal of Cardiovascular Pharmacology*, **2009**, 53, 495-8	3.1	13
3	Combination therapy with beta-adrenergic receptor antagonists and phosphodiesterase inhibitors for chronic heart failure. *Pharmacotherapy*, **2008**, 28, 1523-30	5.8	7
2	Carvedilol increases blood pressure response to phenylephrine infusion in heart failure subjects with systolic dysfunction: evidence of improved vascular alpha1-adrenoreceptor signal transduction. *American Heart Journal*, **2008**, 156, 315-21	4.9	10
1	Aliskiren for renin inhibition: a new class of antihypertensives. *Annals of Pharmacotherapy*, **2007**, 41, 456-64	2.9	26